Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (665)	3/2/1999 10:31:00 PM
From: John Metcalf	Respond to of 2001

<Anyone remember what NXCO went for?> Elan acquired Neurex (announced 4/30/98) for .51 ELN Ads per NXCO share. At the time, ELN traded for $62 5/8 and Neurex had a shade over 22mm shares, so the price was about $700 million. At the time, Corlopam was approved and Ziconotide was moving towards approval. BTW, if you want to watch Elan as a muncher, it's worth noting that Athena also had two late-stage products when acquired by Elan.